RECOMBINANT ALFA-INTERFERON IN RENAL-CELL CARCINOMA - A RANDOMIZED TRIAL OF 2 ROUTES OF ADMINISTRATION

被引:141
作者
MUSS, HB
COSTANZI, JJ
LEAVITT, R
WILLIAMS, RD
KEMPF, RA
POLLARD, R
OZER, H
ZEKAN, PJ
GRUNBERG, SM
MITCHELL, MS
CAPONERA, M
GAVIGAN, M
ERNEST, ML
VENTURI, C
GREINER, J
SPIEGEL, RJ
机构
[1] WAKE FOREST UNIV, BOWMAN GRAY SCH MED, ONCOL RES CTR, WINSTON SALEM, NC 27103 USA
[2] UNIV TEXAS, MED BRANCH, MED CTR, GALVESTON, TX 77550 USA
[3] UNIV MARYLAND, CTR CANC, BALTIMORE, MD 21201 USA
[4] UNIV IOWA, IOWA CITY, IA 52242 USA
[5] UNIV SO CALIF, LOS ANGELES CTY HOSP, LOS ANGELES, CA 90033 USA
[6] UNIV SO CALIF, KENNETH NORRIS JR CANC CTR, LOS ANGELES, CA 90089 USA
[7] UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA
[8] SCHERING CORP, KENILWORTH, NJ USA
关键词
D O I
10.1200/JCO.1987.5.2.286
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:286 / 291
页数:6
相关论文
共 14 条
[11]   LOW INCIDENCE OF SERUM NEUTRALIZING FACTORS IN PATIENTS RECEIVING RECOMBINANT ALFA-2B INTERFERON (INTRON-A) [J].
SPIEGEL, RJ ;
SPICEHANDLER, JR ;
JACOBS, SL ;
ODEN, EM .
AMERICAN JOURNAL OF MEDICINE, 1986, 80 (02) :223-228
[12]  
TRUMP D, 1984, P AN M AM SOC CLIN, V3, P153
[13]  
VUGRIN D, 1985, CANCER TREAT REP, V69, P817
[14]  
WILLIAMS RD, 1984, J UROLOGY, V110, P131